Marrow launches with $173M, with OrbiMed leading the $120M Series B
TLDR
- Marrow launched with $173M: a $53M Series A (Scion, venBio) and a $120M Series B led by OrbiMed.1
- Lead MAR-101 is a preclinical antibody-siRNA conjugate for sickle cell disease and beta thalassemia; data are company-reported.123
- No clinic date has been disclosed; Scion hopes programmes reach the clinic "in the coming year".14
Marrow Therapeutics, a Watertown, Massachusetts company developing "bone marrow-targeted therapies to treat severe blood disorders", announced its launch on 17 November with a combined $173M in Series A and Series B funding.1 The $53M Series A was co-led by Scion Life Sciences and venBio. The $120M Series B was led by OrbiMed, "with participation from all Series A investors" and new funds including RTW Investments, Surveyor Capital (a Citadel company), Opaleye, NEXTBio Capital, Affinity Advisors, KKR, Spruce Street Capital and Columbia Threadneedle Investments.1 Fierce Biotech's headline covers only the $120M Series B, though its text gives the $173M total and the Series A.2 MedCity News reports that Scion formed and incubated Marrow in 2024 and that the Series A was raised early in 2025; CEO Romesh Subramanian said it went unannounced because the company was still securing intellectual property.3 The release gives no valuation.1
The company says its Transferrin Antibody Bioconjugate (TAB) platform uses engineered antibodies that bind the transferrin receptor (TfR1) to deliver payloads to bone marrow.1 Lead candidate MAR-101 is in IND-enabling studies for sickle cell disease and beta thalassemia and is designed to reduce BCL11a and reactivate fetal haemoglobin production.1 MedCity News reports that the payload is a small interfering RNA (siRNA).3 The company says its antibodies avoid the anaemia risk that has limited other TfR1 approaches; Subramanian told Fierce, "We have cracked that nut."12
The efficacy claims rest on the company. Subramanian told MedCity News that monkey data show target engagement in bone marrow, BCL11a knockdown and induction of fetal haemoglobin, and that human-cell tests were on par with or better than ex vivo approaches.3 BioPharma Dive says Marrow has not disclosed when MAR-101 will enter the clinic; Subramanian declined to give MedCity News a timeline, saying only "as soon as feasible".43 Separately, Scion's Aaron Kantoff said the firm was "excited to see Marrow advance its programs into the clinic in the coming year", an investor's hope covering more than one programme.1 Peptide and Protein News notes the company has published no preclinical data and that two further programmes, MAR-201 and MAR-301, have undisclosed targets.5
The pitch is access. Casgevy and Lyfgenia require harvesting and engineering a patient's stem cells and a chemotherapy conditioning regimen, and carry multimillion-dollar price tags, according to BioPharma Dive.4 BioSpace dates their sickle cell approvals to December 2023 and adds that Lyfgenia carries a boxed warning for haematologic cancers.6 Marrow says its treatment would be an injection that could be repeated, BioPharma Dive reports, and MedCity News reports that the company is developing a subcutaneous, self-administered, room-temperature-stable formulation.43
The team comes from Dyne Therapeutics: Subramanian previously led Dyne and Ascidian Therapeutics, and BioSpace says Chief Scientific Officer Tim Weeden and Chief Operating and Technology Officer John Najim also came from Dyne.46 Art Levin, founding chief scientific officer of Avidity Biosciences, has joined the board.1 Novartis agreed in October 2025 to buy Avidity, whose antibody oligonucleotide conjugate platform delivers RNA to muscle, for about $12bn in cash.7 Peptide and Protein News links Levin's seat to Avidity's muscle template, which is untested in bone marrow.5
OrbiMed has backed related genetic medicine companies. In September it provided Intellia, an in vivo CRISPR gene editing company, with a senior secured term loan of up to $400M, with $75M funded at closing; that is debt, not equity.8 MedCity News reported that OrbiMed was the largest shareholder of siRNA developer ADARx, with a 22.7 per cent post-IPO stake, after ADARx raised $446.3M in its September IPO.9 This article did not review other investments by venBio or Scion.
Why it matters: a start-up with no published data raised $173M to test whether an injectable siRNA conjugate can rival one-time gene therapies for sickle cell disease, extending into bone marrow the antibody-oligonucleotide model that Novartis agreed to buy Avidity for, at about $12bn in cash, in muscle.57
Sources
- Marrow Therapeutics Launches With $173 Million to Develop Genetic Medicines for Bone Marrow Disorders (Business Wire (Marrow Therapeutics))
- Marrow extracts $120M series B for blood disease drug (Fierce Biotech)
- Marrow Therapeutics Unveils $173M for 'Trojan Horse' Delivery of Blood Disorder Drugs (MedCity News)
- Marrow sets out to challenge genetic medicines for severe blood diseases (BioPharma Dive)
- Marrow Therapeutics Launches With $173 Million for Bone Marrow-Targeted Oligonucleotide Conjugates (Peptide and Protein News)
- Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo (BioSpace)
- Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline (Novartis)
- Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million (Intellia Therapeutics)
- Gene Silencing Biotech ADARx Makes Some Noise With $535M Stock Market Debut (MedCity News)